RenovoRx is a clinical-stage biopharmaceutical brand that aims to disrupt the current cancer treatment paradigm. Their mission is to revolutionize oncology therapy by delivering innovative and targeted chemotherapy directly to solid tumors using their RenovoTAMP® (RenovoRx Trans-Arterial Micro-Perfusion) therapy platform. By avoiding harsh side effects and improving patient well-being, RenovoRx extends the lives of cancer patients, allowing them to spend more time with loved ones.

RenovoTAMP is a targeted therapy platform that utilizes approved chemotherapeutics with well-established safety and side effect profiles, enhancing their efficacy and safety. RenovoRx's lead product candidate, RenovoGem™, combines gemcitabine with their patented delivery system and is regulated by the FDA as a novel oncology drug product for treating unresectable locally advanced pancreatic cancer. RenovoRx's groundbreaking therapy platform has shown promising results in Phase I/II clinical trials, with a median survival of 27.

9 months compared to the historical average of 12-15 months. They have received Orphan Drug Designations from the FDA for pancreatic cancer and bile duct cancer. RenovoRx's technology is protected by several patents, and they are currently enrolling patients for the Phase III TIGeR-PaC clinical trial in pancreatic cancer.

With a commitment to delivering therapy where it matters most, RenovoRx is revolutionizing cancer treatment and improving the lives of patients